[ad_1]
This week, Infarmed was once again the story of the cover: for the first time, the president of Apifarma spoke about the 70% transfer from Infarmed to Porto. In an interview with newspaper I, João Almeida Lopes – who heads an entity representing about 120 pharmaceutical companies in Portugal – worried about the government's intention and does not hesitate to say that relocation is a mistake
For the official, the report created by the working group convened by the Ministry of Health to evaluate the transfer, which is known in the meantime, is biased. "When we look at the report, it clearly appears to us a biased report that has been made to try to justify the unjustifiable," argued João Almeida Lopes at I.
For the president of Apifarma, the "unjustifiable" is because, In the case of the association that he directs, 106 of its 109 partners in the pharmaceutical industry are in the Lisbon region, while out of the 15 associated industrial units , 10 are also in the Lisbon area. According to Almeida Lopes, changing the city's Infarmed would result in increased costs of the sectoral context, not to mention the effects it would have on the investment of foreign industry in the country.
But long before this interview, Minister Adalberto Campos Fernandes had already read the position of Apifarma. The SUN found that a letter was received in ministry days after the intention was revealed to the country in the same position.
"We can not fail to express the concern that this position gives rise", begins with if read in the document. In the following paragraphs, the president of Apifarma already lists the points of particular concern to him. It is not only necessary to ensure that employees – who hold the skills and knowledge – are transferred so that the relocation of the organization takes place, because it is "essential" that "the interests of the protection of public health and the sick "
The focus is then put on the" functional implications "that the transfer would mean, as well as on the increase in costs for the associates.
In conclusion, the association hopes that "Studies of impact and technical and economic reasons that have advised them", requesting that they be made available to Apifarma [19659008]
[ad_2]
Source link
